Examinando por Materia "Liraglutida"

Seleccione resultados tecleando las primeras letras
Mostrando 1 - 1 de 1
  • Miniatura
    PublicaciónAcceso abierto
    Perfil ponderal metabólico por liraglutida en diabéticos, no diabéticos con obesidad en farmacia Clínica Delgado Auna. Septiembre a octubre 2025
    (Universidad Privada Norbert Wiener, 2026-01-29) Cabrera Maldonado, Deivy Oscar; Andamayo de Castillo, Diana Esmeralda
    Introducction: Obesity is a growing chronic disease with numerous metabolic complications. Liraglutide, a GLP-1 analogue, has demonstrated effectiveness in reducing body weight and improving metabolic indices in obese individuals, with or without diabetes1,2. “Objective” : of this study was to determine the weight and metabolic profile of liraglutide in obese and non-diabetic patients treated at the pharmacy service of Clínica Privada Delgado – Auna, Lima, Peru, between September and October 2025. “Materials and methods” : An observational, descriptive, and cross-sectional study was conducted, based on the analysis of medical records and documented pharmacotherapeutic parameters. The sample consisted of 170 case and 170 control records of patients meeting the inclusion criteria.” Results” : that diabetic patients lost 7.71 kg and reduced their BMI from 36.76 to 34.07. Non-diabetics gained 8.2 kg and their BMI decreased from 36.05 to 33.13 kg. Metabolically, diabetics showed greater improvement: HbA1c decreased from 8.51% to 6.73%, glucose from 164 to 131 mg/dL, triglycerides by −99, and cholesterol by −41. In non diabetics, triglycerides decreased by −53 and cholesterol by −59, with minimal reductions in glucose and HbA1c. “Conclusion” : Significant differences between groups were confirmed (p<0.050), with the odds ratio showing a lower weight response associated with diabetes (weight 1.37; BMI 2.41), thus confirming the clear differences between the two profiles.